Daridorexant is available in Saudi Arabia. The drug, marketed as Quviviq, received approval from the Saudi Food and Drug Authority (SFDA) in December 2023 [1]. It is indicated for the treatment of chronic insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1].
When did Quviviq get approved in Saudi Arabia?
Quviviq was approved by the Saudi Food and Drug Authority (SFDA) in December 2023 [1]. This approval allows for its availability to patients in Saudi Arabia.
What is daridorexant used for?
Daridorexant, sold as Quviviq, is used to treat chronic insomnia. Its indication specifically covers insomnia that involves problems falling asleep or staying asleep [1].
How does daridorexant work?
Daridorexant is a dual orexin receptor antagonist [2]. Orexin is a neurotransmitter that promotes wakefulness. By blocking the action of orexin at its receptors (OX1R and OX2R), daridorexant reduces the wakefulness drive, thereby facilitating sleep [2].
What is the brand name for daridorexant in Saudi Arabia?
The brand name for daridorexant in Saudi Arabia is Quviviq [1].
Where can I find information on drug patents for daridorexant?
Information regarding drug patents for daridorexant can be found on DrugPatentWatch.com [3]. Resources like DrugPatentWatch provide insights into patent status and expiry dates, which are crucial for understanding market exclusivity [3].